MX2009000975A - Metodos para atenuar la liberacion de mediadores inflamatorios y peptidos utiles en ellos. - Google Patents
Metodos para atenuar la liberacion de mediadores inflamatorios y peptidos utiles en ellos.Info
- Publication number
- MX2009000975A MX2009000975A MX2009000975A MX2009000975A MX2009000975A MX 2009000975 A MX2009000975 A MX 2009000975A MX 2009000975 A MX2009000975 A MX 2009000975A MX 2009000975 A MX2009000975 A MX 2009000975A MX 2009000975 A MX2009000975 A MX 2009000975A
- Authority
- MX
- Mexico
- Prior art keywords
- inflammatory mediators
- methods
- present
- release
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención incluye métodos para inhibir o suprimir los procesos secretores celulares. Más en específico, la presente invención se refiere a la inhibición o reducción de la liberación de mediadores inflamatorios desde células inflamatorias, inhibiendo el mecanismo asociado con la liberación de mediadores inflamatorios desde los gránulos de las células inflamatorias. En este sentido, la presente invención describe un mecanismo señalizador intracelular que ilustra varios blancos intracelulares novedosos para intervención farmacológica, en trastornos que implican la secreción de mediadores inflamatorios desde las vesículas de las células inflamatorias. Los fragmentos de péptido y sus variantes del péptido MANS, que están descritos en la presente invención, son útiles en esos métodos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83323906P | 2006-07-26 | 2006-07-26 | |
PCT/US2007/074514 WO2008014414A2 (en) | 2006-07-26 | 2007-07-26 | Methods for attenuating release of inflammatory mediators and peptides useful therein |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009000975A true MX2009000975A (es) | 2009-04-07 |
Family
ID=38982357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009000975A MX2009000975A (es) | 2006-07-26 | 2007-07-26 | Metodos para atenuar la liberacion de mediadores inflamatorios y peptidos utiles en ellos. |
Country Status (22)
Country | Link |
---|---|
US (6) | US8999915B2 (es) |
EP (2) | EP2053915B1 (es) |
JP (2) | JP5378998B2 (es) |
KR (1) | KR101599894B1 (es) |
CN (2) | CN103990111B (es) |
AU (1) | AU2007279193B2 (es) |
BR (1) | BRPI0714953A2 (es) |
CA (2) | CA2842219C (es) |
DK (2) | DK2722052T3 (es) |
ES (2) | ES2488092T3 (es) |
HK (2) | HK1125793A1 (es) |
HR (1) | HRP20140587T1 (es) |
IL (1) | IL196667A (es) |
MX (1) | MX2009000975A (es) |
NO (1) | NO20090304L (es) |
PL (2) | PL2053915T3 (es) |
PT (1) | PT2053915E (es) |
RU (1) | RU2423376C2 (es) |
SG (2) | SG10201500418QA (es) |
SI (1) | SI2053915T1 (es) |
WO (1) | WO2008014414A2 (es) |
ZA (1) | ZA200900550B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006078899A2 (en) | 2005-01-20 | 2006-07-27 | Biomarck Pharmaceuticals, Ltd. | Mucin hypersecretion inhibitors based on the structure of mans and methods of use |
MX2009000975A (es) | 2006-07-26 | 2009-04-07 | Biomarck Pharmaceuticals Ltd | Metodos para atenuar la liberacion de mediadores inflamatorios y peptidos utiles en ellos. |
JP5736370B2 (ja) * | 2009-06-25 | 2015-06-17 | ネステク ソシエテ アノニム | 過敏性腸症候群の診断方法 |
WO2011060349A1 (en) * | 2009-11-13 | 2011-05-19 | North Carolina State University | Methods of modulating mesenchymal stem cells |
CN105517562B (zh) | 2013-04-05 | 2018-12-28 | 拜欧马可医药公司 | 转移抑制剂 |
US10189881B2 (en) | 2013-07-26 | 2019-01-29 | The Regents Of The University Of California | MPS peptides and use thereof |
US10314889B2 (en) | 2013-12-20 | 2019-06-11 | The Regents Of The University Of California | Suppression of allergic lung inflammation and hyperreactivity |
KR102181548B1 (ko) * | 2019-02-20 | 2020-11-20 | 한국외국어대학교 연구산학협력단 | 염증성 질환 또는 자가면역성 질환의 예방 또는 치료 활성을 갖는 펩타이드 및 이의 용도 |
WO2023212443A1 (en) * | 2022-04-25 | 2023-11-02 | Biomarck Pharmaceuticals, Ltd. | Peptides and methods of use thereof in treating skin diseases |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61265341A (ja) * | 1985-05-17 | 1986-11-25 | Kawasaki Heavy Ind Ltd | V型エンジンのシリンダ−ブロツク構造 |
US4873346A (en) * | 1985-09-20 | 1989-10-10 | The Upjohn Company | Substituted benzothiazoles, benzimidazoles, and benzoxazoles |
US4753945A (en) * | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
US4966848A (en) * | 1988-02-08 | 1990-10-30 | The General Hospital Corporation | Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase |
WO1990005744A1 (en) | 1988-11-18 | 1990-05-31 | The Board Of Regents Of The University Of Washington | Hdl-binding proteins |
US5223421A (en) * | 1989-10-25 | 1993-06-29 | The General Hospital Corporation | Identification of methionine Nα-acetyltransferase |
WO1992005784A1 (en) | 1990-10-02 | 1992-04-16 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
US5292498A (en) * | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
WO1993000353A1 (en) | 1991-06-20 | 1993-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sequences characteristic of human gene transcription product |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
EP0551200A1 (en) | 1992-01-07 | 1993-07-14 | National University Of Singapore | Protein phosphatase inhibitors for use in therapy |
US5298506A (en) * | 1992-05-08 | 1994-03-29 | Brigham And Women's Hospital | Use of guanylate cyclase inhibitors in the treatment of shock |
US5861502A (en) * | 1992-11-09 | 1999-01-19 | Thomas Jefferson University | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen |
US5512269A (en) * | 1993-06-09 | 1996-04-30 | Burroughs Wellcome, Co. | Method of treating retained pulmonary secretions |
US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US5858981A (en) * | 1993-09-30 | 1999-01-12 | University Of Pennsylvania | Method of inhibiting phagocytosis |
US5436243A (en) * | 1993-11-17 | 1995-07-25 | Research Triangle Institute Duke University | Aminoanthraquinone derivatives to combat multidrug resistance |
CA2187322A1 (en) | 1994-04-07 | 1995-10-19 | Israel Rubinstein | Vasoactive intestinal polypeptide |
US5985822A (en) | 1994-12-09 | 1999-11-16 | The Scripps Research Institute | Inhibition of glial cell proliferation with N-CAM homophilic peptides |
US6713605B1 (en) * | 1996-04-10 | 2004-03-30 | Kansas State University Research Foundation | Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes |
US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
GB9620390D0 (en) * | 1996-09-30 | 1996-11-13 | Eisai London Res Lab Ltd | Substances and their uses |
DE19716713A1 (de) | 1997-04-21 | 1998-10-22 | Paz Arzneimittelentwicklung | Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz |
US8501911B2 (en) * | 1999-02-24 | 2013-08-06 | Biomarck Pharmaceuticals, Ltd | Methods of reducing inflammation and mucus hypersecretion |
AU766800B2 (en) | 1999-02-24 | 2003-10-23 | North Carolina State University | Methods and compositions for altering mucus secretion |
US7544772B2 (en) * | 2001-06-26 | 2009-06-09 | Biomarck Pharmaceuticals, Ltd. | Methods for regulating inflammatory mediators and peptides useful therein |
US6245320B1 (en) * | 1999-09-01 | 2001-06-12 | University Of Maryland | Inhibition of mucin release from airway goblet cells by polycationic peptides |
WO2001020998A1 (en) | 1999-09-24 | 2001-03-29 | Linden Technologies, Inc. | Drug discovery using gene expression profiling |
EP1104758B1 (en) * | 1999-12-03 | 2003-07-23 | Pfizer Products Inc. | Acetylene derivatives as anti-inflammatory/analgesic agents |
US7919469B2 (en) * | 2000-02-24 | 2011-04-05 | North Carolina State University | Methods and compositions for altering mucus secretion |
US7265088B1 (en) | 2000-02-24 | 2007-09-04 | North Carolina State University | Method and compositions for altering mucus secretion |
ATE519493T1 (de) * | 2001-06-26 | 2011-08-15 | Univ North Carolina State | Blockierendes peptid für die sekretion von entzündungszellen |
JP2004049133A (ja) | 2002-07-22 | 2004-02-19 | Kumamoto Technology & Industry Foundation | N−ミリストイルトランスフェラーゼ活性の測定方法 |
US7598080B2 (en) * | 2004-08-20 | 2009-10-06 | Carl Deirmengian | Diagnostic assay for source of inflammation |
US7408030B2 (en) * | 2005-01-13 | 2008-08-05 | North Carolina State University | Purification of immunoglobulins using affinity chromatography and peptide ligands |
WO2006078899A2 (en) * | 2005-01-20 | 2006-07-27 | Biomarck Pharmaceuticals, Ltd. | Mucin hypersecretion inhibitors based on the structure of mans and methods of use |
MX2009000975A (es) | 2006-07-26 | 2009-04-07 | Biomarck Pharmaceuticals Ltd | Metodos para atenuar la liberacion de mediadores inflamatorios y peptidos utiles en ellos. |
-
2007
- 2007-07-26 MX MX2009000975A patent/MX2009000975A/es active IP Right Grant
- 2007-07-26 KR KR1020097004065A patent/KR101599894B1/ko active IP Right Grant
- 2007-07-26 CA CA2842219A patent/CA2842219C/en active Active
- 2007-07-26 CN CN201410224653.8A patent/CN103990111B/zh active Active
- 2007-07-26 SI SI200731481T patent/SI2053915T1/sl unknown
- 2007-07-26 WO PCT/US2007/074514 patent/WO2008014414A2/en active Application Filing
- 2007-07-26 AU AU2007279193A patent/AU2007279193B2/en active Active
- 2007-07-26 ZA ZA200900550A patent/ZA200900550B/xx unknown
- 2007-07-26 ES ES07840538.8T patent/ES2488092T3/es active Active
- 2007-07-26 SG SG10201500418QA patent/SG10201500418QA/en unknown
- 2007-07-26 BR BRPI0714953-0A2A patent/BRPI0714953A2/pt not_active Application Discontinuation
- 2007-07-26 CN CN200780035710.6A patent/CN101516190B/zh active Active
- 2007-07-26 EP EP07840538.8A patent/EP2053915B1/en active Active
- 2007-07-26 EP EP14151431.5A patent/EP2722052B1/en active Active
- 2007-07-26 SG SG2011053303A patent/SG173411A1/en unknown
- 2007-07-26 DK DK14151431.5T patent/DK2722052T3/en active
- 2007-07-26 DK DK07840538.8T patent/DK2053915T3/da active
- 2007-07-26 RU RU2009106673/04A patent/RU2423376C2/ru active
- 2007-07-26 CA CA2658949A patent/CA2658949C/en active Active
- 2007-07-26 ES ES14151431T patent/ES2725599T3/es active Active
- 2007-07-26 PL PL07840538T patent/PL2053915T3/pl unknown
- 2007-07-26 JP JP2009522007A patent/JP5378998B2/ja not_active Expired - Fee Related
- 2007-07-26 PT PT78405388T patent/PT2053915E/pt unknown
- 2007-07-26 PL PL14151431T patent/PL2722052T3/pl unknown
-
2009
- 2009-01-20 NO NO20090304A patent/NO20090304L/no not_active Application Discontinuation
- 2009-01-22 IL IL196667A patent/IL196667A/en active IP Right Grant
- 2009-01-26 US US12/359,892 patent/US8999915B2/en active Active
- 2009-05-19 HK HK09104579.2A patent/HK1125793A1/xx unknown
-
2013
- 2013-07-11 JP JP2013145459A patent/JP5819889B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-23 HR HRP20140587TT patent/HRP20140587T1/hr unknown
-
2015
- 2015-02-16 HK HK15101730.6A patent/HK1201190A1/xx unknown
- 2015-03-04 US US14/638,208 patent/US9827287B2/en active Active
-
2017
- 2017-10-20 US US15/789,442 patent/US20180036367A1/en not_active Abandoned
-
2018
- 2018-12-28 US US16/235,880 patent/US20200138898A1/en not_active Abandoned
-
2021
- 2021-05-04 US US17/307,471 patent/US20210260154A1/en not_active Abandoned
-
2023
- 2023-04-05 US US18/296,275 patent/US20230293629A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007103368A3 (en) | Methods for regulating inflammatory mediators and peptides useful therein | |
MX2009000975A (es) | Metodos para atenuar la liberacion de mediadores inflamatorios y peptidos utiles en ellos. | |
HUS2100051I1 (hu) | Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére | |
MY171289A (en) | Inhibitors of e1 activating enzymes | |
MX2009001309A (es) | Compuestos de heteroarilo utiles como inhibidores de enzimas de activacion e1. | |
EA200801531A1 (ru) | Способы регулирования содержания маннозы в рекомбинантных белках | |
WO2006023844A3 (en) | Compositions and methods comprising proteinase activated receptor antagonists | |
WO2011024110A3 (en) | Glucagon-like peptide-1 receptor (glp-1r) agonists for treating autoimmune disorders | |
WO2007054623A3 (en) | Mammalian hedgehog signaling inhiabitors | |
EP2185197A4 (en) | NOVEL COMPOSITIONS OF A SOLUTION CONTAINING A CELLULAR FACTOR | |
WO2010129917A3 (en) | Anti-cd100 antibodies and methods for using the same | |
WO2006116381A3 (en) | Plasma or serum fraction for treatment or prevention of abnormal cell proliferation | |
WO2011004028A3 (en) | Tlr3 binding agents | |
WO2007084419A3 (en) | Inhibition of inflammatory cytokine production with tanshinones | |
WO2005117557A3 (en) | Expression system | |
WO2008011071A3 (en) | Interactions of hedgehog and liver x receptor signaling pathways | |
WO2007075439A3 (en) | Compositions and methods for treating obesity and related metabolic disorders | |
MY149606A (en) | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment | |
EP2185514A4 (en) | VINYL-ARYL DERIVATIVES FOR INFLAMMATORY AND IMMUNE DISORDERS | |
TW200740999A (en) | Therapeutic reprogramming of germ-line stem cells | |
EP1963506A4 (en) | COMPOSITIONS AND METHODS FOR INCREASING THE PRODUCTION OF RECOMBINANT GAMMA-CARBOXYLATED PROTEINS | |
UA105073C2 (uk) | Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень | |
WO2010014253A3 (en) | Ant4 inhibitor compounds and methods of use thereof | |
WO2008137122A3 (en) | Inducing premature senescence to stabilize stem cell feeder layer cells | |
EP1971608A4 (en) | spiroketals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |